Apimeds Pharmaceuticals Reports $1.78 Million Net Loss in Q3 2025, IPO Proceeds Boost Cash Reserves

Apimeds Pharmaceuticals US, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company, which is focused on developing Apitox, a proprietary bee venom-based therapeutic, recorded a net loss of $1.78 million for the third quarter, compared to a loss of $332,521 in the same period last year. For the nine months ended September 30, 2025, the net loss totaled $4.85 million, up from $1.08 million in the prior year. The increase in losses is attributed to heightened operational expenses, particularly in research and development, which amounted to $619,693 for the quarter, a stark contrast to no such expenses in the previous year.

The company's total operating expenses for the third quarter reached $1.84 million, significantly higher than the $299,999 reported in the same quarter of 2024. This increase was primarily driven by a rise in general and administrative expenses, which surged to $1.22 million from $299,999, reflecting expanded operational activities and increased stock-based compensation. The company has not generated any revenue to date, as it remains in the clinical stage of product development.

In terms of financial position, Apimeds reported total assets of $9.25 million as of September 30, 2025, a substantial increase from just $13,057 at the end of 2024. This growth is largely due to the successful completion of its initial public offering (IPO) on May 12, 2025, which raised approximately $11.9 million in net proceeds from the sale of 3,375,000 shares at $4.00 each. The IPO allowed the company to bolster its cash reserves, ending the quarter with $6.99 million in cash, compared to just $3,455 at the end of 2024.

Operationally, Apimeds has made strides in its clinical development efforts, having completed a Phase 3 trial for Apitox in 2018. The company is now focused on obtaining FDA approval for the product, which is already marketed in South Korea. The filing indicates that Apimeds plans to explore additional applications for Apitox, including potential treatments for multiple sclerosis. The company’s accumulated deficit has grown to $9.24 million, reflecting ongoing investments in research and development as it seeks to advance its product pipeline.

Looking ahead, Apimeds anticipates continuing to incur substantial losses as it progresses through the regulatory approval process and expands its operational capabilities. The company believes that its current cash position, bolstered by the IPO proceeds, will be sufficient to fund its operations for at least the next twelve months. However, it remains dependent on securing additional financing to support its long-term growth and development objectives.